[go: up one dir, main page]

MX2010002300A - Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos. - Google Patents

Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.

Info

Publication number
MX2010002300A
MX2010002300A MX2010002300A MX2010002300A MX2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A
Authority
MX
Mexico
Prior art keywords
sulfonyl
hydrate
pyridine
tert
benzyl
Prior art date
Application number
MX2010002300A
Other languages
English (en)
Inventor
Joseph Francis Krzyzaniak
David Burns Damon
Jinyang Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2010002300A publication Critical patent/MX2010002300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas polirnárficas o a una forma no cristalina o amorfa del compuesto sal sódica del ácido (3- (((4-terc-butil-bencil)-(piridin-3-sulfon il)-amino)-metil)-fenoxi)-acético o un hidrato del mismo conjuntamente con procedimientos para preparar, procedimientos para usar, y composiciones farmacéuticas que contengan las mismas; la invención se refiere también a formas cristalinas polimórficas sustancialmente puras o una forma no cristalina o forma amorfa de la sal sódica del ácido (3-(((4-terc-butil-bencil) -(piridin-3-sulfonil)-amino)-metll)- fenoxi)-acético o de un hidrato de la misma.
MX2010002300A 2007-08-29 2008-08-25 Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos. MX2010002300A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96877107P 2007-08-29 2007-08-29
US8355908P 2008-07-25 2008-07-25
PCT/IB2008/002252 WO2009027811A2 (en) 2007-08-29 2008-08-25 Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same

Publications (1)

Publication Number Publication Date
MX2010002300A true MX2010002300A (es) 2010-03-18

Family

ID=40042625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002300A MX2010002300A (es) 2007-08-29 2008-08-25 Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.

Country Status (9)

Country Link
EP (1) EP2185516A2 (es)
JP (1) JP2009137934A (es)
KR (1) KR20100050559A (es)
CN (1) CN101842356A (es)
AR (1) AR068349A1 (es)
AU (1) AU2008291814A1 (es)
CA (1) CA2697950A1 (es)
MX (1) MX2010002300A (es)
WO (1) WO2009027811A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700121T1 (it) * 2009-02-27 2017-03-08 Janssen Pharmaceuticals Inc Sale amorfo di un inibitore macrociclico di hcv
SG11202007544RA (en) * 2018-02-28 2020-09-29 Bridge Biotherapeutics Inc Water soluble salts of lipidated peptides and methods for preparing and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
KR20100050559A (ko) 2010-05-13
CN101842356A (zh) 2010-09-22
EP2185516A2 (en) 2010-05-19
WO2009027811A2 (en) 2009-03-05
AU2008291814A1 (en) 2009-03-05
CA2697950A1 (en) 2009-03-05
WO2009027811A3 (en) 2009-06-11
JP2009137934A (ja) 2009-06-25
AR068349A1 (es) 2009-11-11

Similar Documents

Publication Publication Date Title
WO2007141283A3 (en) Salts and crystalline salt forms of an 2-indolinone derivative
WO2011127290A3 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
WO2012138147A3 (en) 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
MX2011007978A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
TN2009000167A1 (en) Crystalline potassium salt of lipoxin a4 analogs
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
WO2010079045A3 (en) Crystalline salt forms of flibanserine
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds
WO2008015703A3 (en) Process for the preparation of montelukast and its salts thereof
MX2010001864A (es) Metodo para la preparacion de acido montelukast en un medio liquido ionico.
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2008081476A3 (en) Process for preparing duloxetine hydrochloride
MX2012001722A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
WO2011135586A3 (en) Process for the preparation of chiral beta amino carboxamide derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal